JP2019510798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510798A5 JP2019510798A5 JP2018552846A JP2018552846A JP2019510798A5 JP 2019510798 A5 JP2019510798 A5 JP 2019510798A5 JP 2018552846 A JP2018552846 A JP 2018552846A JP 2018552846 A JP2018552846 A JP 2018552846A JP 2019510798 A5 JP2019510798 A5 JP 2019510798A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- solvate
- acceptable salt
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 123
- 239000012453 solvate Substances 0.000 claims description 121
- 150000001875 compounds Chemical class 0.000 claims description 104
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 27
- 150000002431 hydrogen Chemical class 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000005466 alkylenyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- -1 alkylenyl compound Chemical class 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 10
- 208000000587 small cell lung carcinoma Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 6
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
- 201000004101 esophageal cancer Diseases 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000003757 neuroblast Anatomy 0.000 description 5
- 0 C[C@@]([C@](C(*)N*)N(**)[C@@]1(*)**)[C@@]11c(cccc2)c2NC1=* Chemical compound C[C@@]([C@](C(*)N*)N(**)[C@@]1(*)**)[C@@]11c(cccc2)c2NC1=* 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JLQHICJMQYMTDQ-RKUZKHJWSA-N O=C([C@@H]([C@@H]1c(cccc2Cl)c2F)NC2(CCCCC2)[C@@]1(c(c(N1)c2)ccc2Cl)C1=O)Nc(cc1)ccc1C(NCCCCOc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)=O Chemical compound O=C([C@@H]([C@@H]1c(cccc2Cl)c2F)NC2(CCCCC2)[C@@]1(c(c(N1)c2)ccc2Cl)C1=O)Nc(cc1)ccc1C(NCCCCOc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)=O JLQHICJMQYMTDQ-RKUZKHJWSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022033173A JP2022078201A (ja) | 2016-04-06 | 2022-03-04 | Ｍｄｍ２タンパク質分解剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318974P | 2016-04-06 | 2016-04-06 | |
| US62/318,974 | 2016-04-06 | ||
| US201662393874P | 2016-09-13 | 2016-09-13 | |
| US62/393,874 | 2016-09-13 | ||
| US201662409571P | 2016-10-18 | 2016-10-18 | |
| US62/409,571 | 2016-10-18 | ||
| PCT/US2017/026274 WO2017176957A1 (en) | 2016-04-06 | 2017-04-06 | Mdm2 protein degraders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022033173A Division JP2022078201A (ja) | 2016-04-06 | 2022-03-04 | Ｍｄｍ２タンパク質分解剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510798A JP2019510798A (ja) | 2019-04-18 |
| JP2019510798A5 true JP2019510798A5 (enExample) | 2020-03-19 |
| JP7037500B2 JP7037500B2 (ja) | 2022-03-16 |
Family
ID=58549316
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552846A Active JP7037500B2 (ja) | 2016-04-06 | 2017-04-06 | Ｍｄｍ２タンパク質分解剤 |
| JP2022033173A Pending JP2022078201A (ja) | 2016-04-06 | 2022-03-04 | Ｍｄｍ２タンパク質分解剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022033173A Pending JP2022078201A (ja) | 2016-04-06 | 2022-03-04 | Ｍｄｍ２タンパク質分解剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192898B2 (enExample) |
| EP (1) | EP3440066B1 (enExample) |
| JP (2) | JP7037500B2 (enExample) |
| KR (1) | KR102387316B1 (enExample) |
| CN (2) | CN113788818A (enExample) |
| AU (1) | AU2017246452C1 (enExample) |
| IL (1) | IL262103B (enExample) |
| MX (1) | MX2018012174A (enExample) |
| RU (2) | RU2743432C2 (enExample) |
| SG (1) | SG11201808728QA (enExample) |
| UA (1) | UA123786C2 (enExample) |
| WO (1) | WO2017176957A1 (enExample) |
| ZA (1) | ZA201806968B (enExample) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018526430A (ja) | 2015-07-10 | 2018-09-13 | アルヴィナス・インコーポレイテッド | タンパク質分解のｍｄｍ２系修飾因子および関連の使用方法 |
| CN113788818A (zh) * | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| JP6968823B2 (ja) | 2016-04-22 | 2021-11-17 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｇｆｒの分解のための二官能性分子、及び使用方法 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN118834201A (zh) | 2016-12-01 | 2024-10-25 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| JP2020506922A (ja) | 2017-01-31 | 2020-03-05 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019014100A1 (en) | 2017-07-10 | 2019-01-17 | Celgene Corporation | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| EP3778590A4 (en) | 2018-04-09 | 2021-12-22 | ShanghaiTech University | ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE |
| CN112312904B (zh) | 2018-04-16 | 2025-01-07 | C4医药公司 | 螺环化合物 |
| SG11202009237XA (en) | 2018-04-23 | 2020-10-29 | Celgene Corp | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| WO2019213005A1 (en) * | 2018-04-30 | 2019-11-07 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (pbrm1) |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN108864113B (zh) * | 2018-08-03 | 2021-08-13 | 南方科技大学 | 一种mdm2-hdac双靶点抑制剂、药物组合物及其制备和用途 |
| KR20210073490A (ko) * | 2018-08-08 | 2021-06-18 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | 면역요법과 mdm2 억제제의 병용 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| IL280984B2 (en) | 2018-08-22 | 2025-02-01 | Cullgen Shanghai Inc | Tropomyosin receptor kinase (TRK) inhibitor compounds and methods of use |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| CN110963958B (zh) * | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| EP3863720A1 (en) * | 2018-10-08 | 2021-08-18 | The Regents Of The University Of Michigan | Small molecule mdm2 protein degraders |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| AU2019381688A1 (en) | 2018-11-13 | 2021-06-03 | Biotheryx, Inc. | Substituted isoindolinones |
| CN111214468B (zh) * | 2018-11-23 | 2021-02-05 | 苏州亚盛药业有限公司 | 新型药物组合物及其用途 |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3095702A1 (en) * | 2018-12-14 | 2020-06-18 | Ascentage Pharma (Suzhou) Co., Ltd. | A compound for treating osteoarthritis |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| US11098025B2 (en) | 2019-01-30 | 2021-08-24 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US11547759B2 (en) | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| JP2022527114A (ja) | 2019-04-05 | 2022-05-30 | カイメラ セラピューティクス， インコーポレイテッド | 分解剤およびそれらの使用 |
| US20220251071A1 (en) * | 2019-05-14 | 2022-08-11 | Wisconsin Alumni Research Foundation | Method to make small-molecule murine double minute 2 protein (mdm2)-degrading compounds, compounds formed thereby, and pharmaceutical compositions containing them |
| US12521438B2 (en) | 2019-06-10 | 2026-01-13 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| MX2021015995A (es) | 2019-06-28 | 2022-03-11 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| WO2021004516A1 (en) * | 2019-07-11 | 2021-01-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing 2-indolinospirone compound and intermediate thereof |
| CN114867727B (zh) | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN112321566B (zh) | 2019-08-05 | 2022-06-10 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CN119019369A (zh) | 2019-10-17 | 2024-11-26 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| CN112745298B (zh) * | 2019-10-30 | 2024-04-09 | 中国科学院上海药物研究所 | 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途 |
| AR120481A1 (es) | 2019-11-19 | 2022-02-16 | Bristol Myers Squibb Co | Compuestos útiles como inhibidores de la proteína helios |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN115052627A (zh) | 2019-12-17 | 2022-09-13 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| PE20221582A1 (es) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos |
| US11850239B2 (en) | 2019-12-19 | 2023-12-26 | Ascentage Pharma (Suzhou) Co., Ltd. | MDM2 inhibitor and a platinum compound for cancer treatment |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| CN113149998B (zh) * | 2020-01-23 | 2024-05-31 | 苏州亚盛药业有限公司 | 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式 |
| EP4110772A4 (en) | 2020-02-26 | 2024-04-03 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE |
| MX2022010952A (es) | 2020-03-05 | 2022-10-07 | C4 Therapeutics Inc | Compuestos para la degradacion dirigida de brd9. |
| EP4122925A4 (en) * | 2020-03-17 | 2024-04-17 | Medshine Discovery Inc. | Proteolysis regulator and method for using same |
| MX2022011602A (es) * | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| CN113509557A (zh) * | 2020-04-09 | 2021-10-19 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| JP2023534528A (ja) * | 2020-07-20 | 2023-08-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
| JP2023538517A (ja) | 2020-08-05 | 2023-09-08 | シーフォー セラピューティクス， インコーポレイテッド | Ｒｅｔの標的分解のための化合物 |
| US20230313313A1 (en) | 2020-08-27 | 2023-10-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US20240024494A1 (en) * | 2020-09-11 | 2024-01-25 | Shanghai Mewsgen Biotechnology Co., Ltd | Small-molecule conjugate and use thereof |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| CA3202360A1 (en) | 2020-12-30 | 2022-07-07 | Nello Mainolfi | Irak degraders and uses thereof |
| WO2022159644A1 (en) | 2021-01-23 | 2022-07-28 | Newave Pharmaceutical Inc. | Spirocyclic mdm2 modulator and uses thereof |
| CN114853731B (zh) * | 2021-02-04 | 2026-02-06 | 上海长森药业有限公司 | 一种双功能mdm2蛋白降解剂，及其制备方法、药物组合物和应用 |
| CA3207049A1 (en) | 2021-02-15 | 2022-08-18 | Jared Gollob | Irak4 degraders and uses thereof |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| SI4320112T1 (sl) | 2021-04-06 | 2025-09-30 | Bristol-Myers Squibb Company | Oksoizoindolin spojine, substituirane s piridinilom |
| CN118388454A (zh) | 2021-04-16 | 2024-07-26 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| CA3217417A1 (en) | 2021-05-05 | 2022-11-10 | Kevin M. Guckian | Compounds for targeting degradation of bruton's tyrosine kinase |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| UY39844A (es) | 2021-07-07 | 2023-01-31 | Biogen Ma Inc | Compuestos para la degradación selectiva de las proteínas irak4 |
| JP2024525580A (ja) | 2021-07-07 | 2024-07-12 | バイオジェン・エムエイ・インコーポレイテッド | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 |
| AU2022306297A1 (en) | 2021-07-09 | 2024-02-08 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| US11981672B2 (en) | 2021-09-13 | 2024-05-14 | Montelino Therapeutics Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| CN117916241A (zh) | 2021-09-13 | 2024-04-19 | 阿斯利康(瑞典)有限公司 | 螺环化合物 |
| EP4405359A4 (en) * | 2021-09-22 | 2025-08-06 | Kymera Therapeutics Inc | MDM2 DEGRADING AGENTS AND THEIR USES |
| CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| JP2024546854A (ja) * | 2021-12-15 | 2024-12-26 | カイメラ セラピューティクス， インコーポレイテッド | がんの処置方法 |
| CN113979999B (zh) * | 2021-12-23 | 2022-05-20 | 北京鑫开元医药科技有限公司 | 靶向泛素化降解bcr-abl激酶的化合物及其制备方法、组合物和用途 |
| US12091411B2 (en) | 2022-01-31 | 2024-09-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2023230059A1 (en) * | 2022-05-24 | 2023-11-30 | Newave Pharmaceutical Inc. | Mdm2 degrader |
| WO2024006776A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and medical use thereof |
| WO2024006781A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and use thereof |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN118047784B (zh) * | 2022-10-13 | 2025-09-16 | 中国科学院上海药物研究所 | 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物 |
| WO2024097948A1 (en) | 2022-11-04 | 2024-05-10 | Roivant Discovery, Inc. | Degraders of mdm2 and uses thereof |
| US20260053931A1 (en) * | 2023-01-05 | 2026-02-26 | The Wistar Institute Of Anatomy And Biology | Mdm2 targeting protacs |
| WO2024187066A1 (en) * | 2023-03-08 | 2024-09-12 | Regents Of The University Of Michigan | Compounds and compositions as cbp/p300 degraders and uses thereof |
| WO2024197219A1 (en) * | 2023-03-22 | 2024-09-26 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| KR20240166948A (ko) * | 2023-05-18 | 2024-11-26 | 아주대학교산학협력단 | 골 분화 유도 가능한 신규 화합물 |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| PT989131E (pt) | 1996-09-13 | 2003-03-31 | Mitsubishi Pharma Corp | Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais |
| US6831155B2 (en) | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| WO2003051360A1 (en) | 2001-12-18 | 2003-06-26 | F. Hoffmann-La Roche Ag | Cis-imidazolines as mdm2 inhibitors |
| DE60225719T2 (de) | 2001-12-18 | 2009-04-23 | F. Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren |
| US8146941B2 (en) * | 2002-05-17 | 2012-04-03 | Steins Karl M | Collapsible trailer |
| US7514579B2 (en) | 2002-06-13 | 2009-04-07 | Johns Hopkins University | Boronic chalcone derivatives and uses thereof |
| WO2004043371A2 (en) | 2002-11-08 | 2004-05-27 | Irm Llc | Methods and compositions for modulating p53 transcription factor |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| EP1633749A4 (en) | 2003-02-13 | 2011-03-02 | Us Gov Health & Human Serv | Deazaflavin compounds and methods of use thereof |
| US6916833B2 (en) | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| WO2005063774A1 (en) | 2003-12-22 | 2005-07-14 | Johns Hopkins University | Boronic acid aryl analogs |
| WO2005097820A1 (en) | 2004-04-06 | 2005-10-20 | Korea Research Institute Of Bioscience And Biotechnology | Peptides for inhibiting mdm2 function |
| MXPA06013246A (es) | 2004-05-18 | 2007-02-08 | Hoffmann La Roche | Nuevas imidazolinas cis. |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| NZ553646A (en) | 2004-09-22 | 2010-07-30 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and p53 |
| EA019566B1 (ru) | 2005-02-22 | 2014-04-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Низкомолекулярные ингибиторы mdm2 |
| SG176463A1 (en) | 2005-02-22 | 2011-12-29 | Univ Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| US7579368B2 (en) | 2005-03-16 | 2009-08-25 | Hoffman-La Roche Inc. | Cis-imidazolines |
| EP1887008B1 (en) | 2005-05-30 | 2021-04-21 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| JP5385125B2 (ja) | 2006-03-22 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ＭＤＭ２とｐ５３の間の相互作用の阻害剤 |
| EA016145B1 (ru) * | 2006-08-30 | 2012-02-28 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Новые низкомолекулярные ингибиторы mdm2 и их применение |
| US7737174B2 (en) | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| KR20090090383A (ko) | 2006-12-14 | 2009-08-25 | 다이이찌 산쿄 가부시키가이샤 | 이미다조티아졸 유도체 |
| MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| WO2008106507A2 (en) | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
| AR065860A1 (es) | 2007-03-29 | 2009-07-08 | Novartis Ag | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
| CA2924436A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use |
| WO2009037343A1 (en) | 2007-09-21 | 2009-03-26 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between mdm2 and p53 |
| EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMORAL MEDIUM |
| EP2298778A4 (en) | 2008-06-12 | 2011-10-05 | Daiichi Sankyo Co Ltd | IMIDAZOTHIAZOL DERIVATIVE WITH 4,7-DIAZASPIRO [2.5] OCTAN RING STRUCTURE |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| DK2421533T3 (en) | 2009-04-22 | 2019-01-07 | Resverlogix Corp | Hitherto unknown anti-inflammatory agents |
| DE102009051823A1 (de) | 2009-11-04 | 2011-05-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Einkristallines Schweißen von direktional verfestigten Werkstoffen |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| KR20120097508A (ko) | 2009-11-05 | 2012-09-04 | 글락소스미스클라인 엘엘씨 | 벤조디아제핀 브로모도메인 억제제 |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| KR20120099462A (ko) | 2009-11-12 | 2012-09-10 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 스피로-옥신돌 ｍｄｍ2 길항제 |
| US20110118283A1 (en) | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8981083B2 (en) | 2010-05-14 | 2015-03-17 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| JP5913292B2 (ja) | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 代謝を調節する組成物および方法 |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| MX2013005238A (es) * | 2010-11-12 | 2013-09-02 | Univ Michigan | Antagonistas de mdm2 de espiro-oxindol. |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| DK2684880T3 (en) * | 2011-03-10 | 2018-05-22 | Daiichi Sankyo Co Ltd | DISPIROPYRROLIDINE DERIVATIVES |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| BR112013028983A2 (pt) | 2011-05-11 | 2017-02-07 | Sanofi Sa | antagonistas mdm2 espiro-oxindol |
| US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20130245089A1 (en) | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CA2870931A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
| AU2012382373A1 (en) | 2012-06-12 | 2014-12-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| EP2970312B1 (en) * | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| US9580430B2 (en) * | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| US10138251B2 (en) * | 2014-04-11 | 2018-11-27 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors |
| JP6778114B2 (ja) * | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| MX373045B (es) * | 2014-04-17 | 2020-05-26 | Univ Michigan Regents | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. |
| JP6503386B2 (ja) | 2014-07-03 | 2019-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| ES2959097T3 (es) * | 2014-08-18 | 2024-02-20 | Hudson Biopharma Inc | Espiropirrolidinas como inhibidores de MDM2 |
| MX373033B (es) | 2014-08-21 | 2020-05-27 | Boehringer Ingelheim Int | Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. |
| WO2016138332A1 (en) * | 2015-02-27 | 2016-09-01 | The Regents Of The University Of Michigan | 9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors |
| WO2017030814A1 (en) * | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| CN113788818A (zh) * | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| AU2017246453A1 (en) * | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| EP3863720A1 (en) * | 2018-10-08 | 2021-08-18 | The Regents Of The University Of Michigan | Small molecule mdm2 protein degraders |
-
2017
- 2017-04-06 CN CN202111145294.3A patent/CN113788818A/zh active Pending
- 2017-04-06 WO PCT/US2017/026274 patent/WO2017176957A1/en not_active Ceased
- 2017-04-06 MX MX2018012174A patent/MX2018012174A/es unknown
- 2017-04-06 UA UAA201810884A patent/UA123786C2/uk unknown
- 2017-04-06 SG SG11201808728QA patent/SG11201808728QA/en unknown
- 2017-04-06 US US16/091,541 patent/US11192898B2/en active Active
- 2017-04-06 JP JP2018552846A patent/JP7037500B2/ja active Active
- 2017-04-06 RU RU2018138735A patent/RU2743432C2/ru active
- 2017-04-06 RU RU2021102253A patent/RU2021102253A/ru unknown
- 2017-04-06 CN CN201780034689.1A patent/CN109415336B/zh active Active
- 2017-04-06 AU AU2017246452A patent/AU2017246452C1/en active Active
- 2017-04-06 KR KR1020187032122A patent/KR102387316B1/ko active Active
- 2017-04-06 EP EP17718290.4A patent/EP3440066B1/en active Active
-
2018
- 2018-10-03 IL IL262103A patent/IL262103B/en active IP Right Grant
- 2018-10-18 ZA ZA2018/06968A patent/ZA201806968B/en unknown
-
2021
- 2021-08-31 US US17/462,355 patent/US20220411432A1/en active Pending
-
2022
- 2022-03-04 JP JP2022033173A patent/JP2022078201A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510798A5 (enExample) | ||
| RU2021102253A (ru) | Деструкторы белка mdm2 | |
| JP2019526615A5 (enExample) | ||
| IL274936B2 (en) | Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors | |
| JP2020007311A5 (enExample) | ||
| JP2019526616A5 (enExample) | ||
| JP2016538313A5 (enExample) | ||
| JP2016505512A5 (enExample) | ||
| JP2006524660A5 (enExample) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2021502387A5 (enExample) | ||
| JP2019512505A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2019510796A5 (enExample) | ||
| JP2019511528A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| FI3436461T3 (fi) | Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina | |
| JP2017508789A5 (enExample) | ||
| JP2013542996A5 (enExample) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2017528487A5 (enExample) | ||
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| JP2015535277A5 (enExample) | ||
| JP2013505917A5 (enExample) |